Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

faldaprevir

Board member Engelbert Tjeenk Willink to leave Boehringer

Replaced by head of established markets Allan Hillgrove

Novartis drug effective in hard-to-treat psoriasis

Secukinumab to commence phase III trials

Novartis building

Novartis heart failure candidate clears phase III trial

Serelaxin proves effective in reducing all-cause mortality

EMA recommends Lilly’s erectile dysfunction drug for enlarged prostate

Cialis would be first drug available in Europe for both ED and BPH

Almirall’s IBS drug Constella backed by CHMP

On track to become the first drug specifically approved for the condition

- PMLiVE

Vivus expects knockback from EMA for obesity drug

Setback comes despite US approval for Qsiva/Qsymia

Novartis building

CHMP backs trio of Novartis products

Including two diabetes drugs and one for non-cancerous kidney tumours

Bayer files low dose contraceptive patch for EU approval

Will offer alternative to J&J’s Evra

Novartis building

Novartis signs $665m option deal with Selexys

Would acquire biotech company and its sickle cell disease drug

- PMLiVE

Boehringer cancer R&D programme bears first fruit

Submits afatinib in Europe to treat lung cancer

- PMLiVE

Sweden’s Tomas Salmonson to chair EMA’s CHMP

He replaces Eric Abadie who retired in April

- PMLiVE

EMA to consult children when reviewing paediatric medicines

Consultation launched on how best to obtain views of young people

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links